Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Troxacitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troxacitabine SCHEMBL1653267 | 0.99 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL1026148 | 0.99 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL18548 | 0.99 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL6424800 | 0.99 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL1844439 | 0.99 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL30317744 | 0.99 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL1026150 | 0.99 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL17542009 | 0.94 | LMNA (0.56) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL7560355 | 0.88 | POLG (0.59) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL31347648 | 0.87 | LMNA (0.59) | LMNAPDE3ACACNA1FALBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731959-B2 | Troxacitabine synthesis and crystal form thereof | BEIJING HEBABIZ BIOTECHNOLOGY CO., INC. (CN) | 2023-08-22 | — | — | US | disclosed |
| US-20200247787-A1 | TROXACITABINE SYNTHESIS AND CRYSTAL FORM THEREOF | BEIJING HEBABIZ BIOTECHNOLOGY CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| CN-105503838-B | The synthesis of troxacitabine and its crystal formation | 广西慧宝源医药科技有限公司 | 2017-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731959-B2 | Troxacitabine synthesis and crystal form thereof | TBXAS1, TTPA, TBCB | POLA1 2452/4885LMNA 2641/4885PDE3A 3102/4885 |
| US-20200247787-A1 | TROXACITABINE SYNTHESIS AND CRYSTAL FORM THEREOF | TBXAS1, TTPA, TBCB | POLA1 2452/4885LMNA 2641/4885PDE3A 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.